ADMA Biologics (NASDAQ:ADMA) Stock Price Down 8.1% – Should You Sell?

ADMA Biologics Inc (NASDAQ:ADMA) shares dropped 8.1% on Wednesday . The stock traded as low as $14.87 and last traded at $14.8350. Approximately 3,540,730 shares changed hands during trading, an increase of 28% from the average daily volume of 2,770,198 shares. The stock had previously closed at $16.15.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ADMA. Zacks Research upgraded shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 2nd. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. Finally, Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Two research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $32.00.

ADMA Biologics Trading Down 8.0%

The company has a market capitalization of $3.54 billion, a P/E ratio of 24.76 and a beta of 0.51. The company has a 50-day simple moving average of $16.55 and a 200 day simple moving average of $16.69. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.74 and a current ratio of 6.71.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.20. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The business had revenue of $139.16 million for the quarter, compared to the consensus estimate of $139.80 million. During the same quarter last year, the company posted $0.46 earnings per share. ADMA Biologics’s quarterly revenue was up 18.4% on a year-over-year basis. Sell-side analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insider Buying and Selling at ADMA Biologics

In related news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the sale, the chief operating officer owned 466,600 shares in the company, valued at approximately $7,292,958. This trade represents a 2.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Steve Elms bought 7,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were purchased at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the transaction, the director owned 2,038,730 shares of the company’s stock, valued at $31,946,899.10. This represents a 0.34% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 3.70% of the company’s stock.

Institutional Trading of ADMA Biologics

Hedge funds have recently modified their holdings of the company. Salomon & Ludwin LLC acquired a new stake in shares of ADMA Biologics during the 3rd quarter worth approximately $25,000. Rothschild Investment LLC lifted its position in ADMA Biologics by 373.8% in the third quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,495 shares during the period. Summit Securities Group LLC acquired a new stake in ADMA Biologics during the fourth quarter worth $29,000. Clearstead Advisors LLC increased its holdings in ADMA Biologics by 55.7% in the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 795 shares during the period. Finally, iSAM Funds UK Ltd bought a new stake in ADMA Biologics in the 3rd quarter valued at $34,000. Institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.